Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 846 of 5804
-
Double immune attack: new combo therapy shows promise for tough melanoma
Disease control CompletedThis randomized phase II trial studies how well ipilimumab with or without high-dose recombinant interferon alpha-2b works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab, may block tumor growth by targe…
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jul 23, 2026 00:00 UTC
-
Brain gene therapy tested for Parkinson's
Disease control CompletedBackground: \- Glial cell line-derived neurotrophic factor (GDNF) is a chemical that may help protect and strengthen brain cells that produce dopamine. Dopamine is a chemical that affects brain function. People with Parkinson's disease (PD) have problems producing dopamine in th…
Phase: PHASE1 • Sponsor: National Institute of Neurological Disorders and Stroke (NINDS) • Aim: Disease control
Last updated Jul 18, 2026 00:00 UTC
-
Drug cocktail shows promise against rare bone marrow cancers
Disease control CompletedThis phase II trial studies how well ruxolitinib phosphate and azacytidine work in treating patients with myelofibrosis or myelodysplastic syndrome/myeloproliferative neoplasm. Ruxolitinib phosphate may stop the growth of cancer cells by blocking some of the enzymes needed for ce…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:01 UTC
-
New drug combo tested against standard care in prostate cancer
Disease control CompletedThe purpose of this study is to compare overall survival in newly diagnosed metastatic prostate cancer patients randomly assigned to androgen deprivation therapy (ADT) + TAK-700 versus ADT + bicalutamide.
Phase: PHASE3 • Sponsor: SWOG Cancer Research Network • Aim: Disease control
Last updated Jun 27, 2026 08:07 UTC
-
5-Day radiation blast shows promise for containing spread of solid tumors
Disease control CompletedThis is a prospective Phase II study.The purpose of this study is to monitor the side effects and treatment outcomes of delivering higher doses of radiation therapy to the tumour, while limiting the dose of radiation to the normal tissues. This will be done using a 5 day treatmen…
Phase: PHASE2 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 09:10 UTC
-
Proton therapy breakthrough: fewer radiation sessions could boost lung cancer survival
Disease control OngoingThe purpose of this research study is to compare the effects (good and bad) on subjects and their cancer using standard chemotherapy in combination with hypofractionated proton radiation therapy. Hypofractionation is a technique that delivers higher daily doses of radiation over …
Phase: PHASE1, PHASE2 • Sponsor: Proton Collaborative Group • Aim: Disease control
Last updated Jun 26, 2026 15:10 UTC
-
Heated chemotherapy showdown: which works better for abdominal cancer spread?
Disease control OngoingThis is the first randomized trial comparing Early post-operative intraperitoneal chemotherapy (EPIC) and hyperthermic intraperitoneal chemotherapy (HIPEC) for appendiceal and colorectal cancer. The purpose of this study is to find out what effects, good and/or bad, EPIC and HIPE…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:03 UTC
-
New proton combo aims to improve esophageal cancer treatment
Disease control Recruiting nowThe goal of this phase II study is to investigate the feasibility, toxicity and efficacy of a regimen incorporating a proven systemic regimen, carboplatin /paclitaxel, with conformal proton modality, followed by definitive surgery. In most combined-modality trials to date, chemot…
Phase: NA • Sponsor: Loma Linda University • Aim: Disease control
Last updated Jun 27, 2026 13:02 UTC
-
New combo therapy may delay prostate cancer's return
Disease control OngoingThis phase II trial studies how well finite androgen ablation with or without abiraterone acetate and prednisone work in treating patients with prostate cancer that has come back. Androgen can cause the growth of prostate cancer cells. Hormone therapy, such as finite androgen abl…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC
-
New drug combo shows promise in preventing deadly transplant complication
Disease control CompletedThis is a phase II multi-center, randomized, double blind, placebo-controlled trial. The investigators are doing this study to see if a new drug, abatacept, can be used together with a calcineurin inhibitor (cyclosporine or tacrolimus) and methotrexate to provide better protecti…
Phase: PHASE2 • Sponsor: Boston Children's Hospital • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
Proton beam zaps breast tumors with less damage?
Disease control Recruiting nowThe purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with early stage breast cancer. A clinical stud…
Phase: PHASE2 • Sponsor: Proton Collaborative Group • Aim: Disease control
Last updated Jun 26, 2026 15:14 UTC
-
Glow-in-the-Dark dye could help brain cancer surgery
Disease control CompletedGlioblastoma is the most frequent primary malignant brain tumor in adults (3,000 new cases per year) and is characterized by a poor prognosis (median survival 12 months). Treatment is based mainly on surgical excision as complete as possible followed by an additional radiochemoth…
Phase: PHASE3 • Sponsor: Hospices Civils de Lyon • Aim: Disease control
Last updated Jun 26, 2026 17:21 UTC
-
New hope for leukemia patients who failed standard treatments
Disease control Recruiting nowThis phase II trial studies how well ponatinib hydrochloride works as second line therapy in treating patients with chronic myeloid leukemia in chronic phase that has not responded to initial treatment (first line) with imatinib mesylate, dasatinib, or nilotinib or cannot tolerat…
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 11:00 UTC
-
Can early chemo beat the clock against colon cancer?
Disease control OngoingThis study sets up the final study end point and three detailed goals as the following. The main objective of study: This trial is done to assess the safety and benefit of early adjuvant chemotherapy from 10 to 14 days after surgery compared with conventional commencement after …
Phase: PHASE3 • Sponsor: Kyungpook National University Hospital • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New drug cocktail aims to deepen remissions in myeloma patients
Disease control CompletedThis phase II trial studies how well carfilzomib, lenalidomide, and dexamethasone before and after stem cell transplant works in treating patients with newly diagnosed multiple myeloma. Carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cel…
Phase: PHASE2 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New ECG technology aims to spot hidden heart disease before the first heart attack
Diagnosis Recruiting nowCardiovascular disease (CVD) is the leading cause of death worldwide. Most individuals with CVD show no evidence of disease for decades as the disease progresses before the first onset of symptoms, often a "sudden" heart attack, finally arises. The spatial repolarization heteroge…
Sponsor: National Taiwan University Hospital • Aim: Diagnosis
Last updated Jul 22, 2026 00:00 UTC
-
New Two-Step transplant shows promise for tough blood cancers
Disease control CompletedThis phase II trial studies reduced-intensity conditioning before donor stem cell transplant in treating patients with high-risk hematologic malignancies. Giving low-doses of chemotherapy and total-body irradiation before a donor stem cell transplant helps stop the growth of canc…
Phase: PHASE2 • Sponsor: Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New hope for hepatitis c: triple therapy shows promise in late-stage trial
Disease control CompletedThis study will evaluate the efficacy and safety of MP-424 with IFN beta and RBV in patients with genotype 1/2 hepatitis C, who are treatment-naïve or have received its treatment before.
Phase: PHASE3 • Sponsor: Tanabe Pharma Corporation • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC
-
Blood transfusion showdown: can more red cells save preemie brains?
Disease control CompletedThe objective of the TOP trial is to determine whether higher hemoglobin thresholds for transfusing ELBW infants resulting in higher hemoglobin levels lead to improvement in the primary outcome of survival and rates of neurodevelopmental impairment (NDI) at 22-26 months of age, u…
Phase: NA • Sponsor: NICHD Neonatal Research Network • Aim: Disease control
Last updated Jun 27, 2026 07:57 UTC
-
New drug combo aims to speed immune recovery after stem cell transplant
Disease control OngoingThe purpose of this study is to help determine if palifermin and leuprolide acetate can help the immune system recover faster following a stem cell transplant. Blood stem cells are very young blood cells that grow in the body to become red or white blood cells or platelets. The t…
Phase: PHASE2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC